Yahoo奇摩 網頁搜尋

  1. 218.50
    +19.50 (+9.80%)
    • 昨收
      199.00
      開盤
      218.00
      委買價
      218.50
      委賣價
      218.50
    • 今日股價區間
      212.00 - 218.50
      52週股價區間
      83.40 - 417.00
      成交量
      3297 張
      平均成交量
      3489 張
    • 市值
      46.390 億
      本益比 (最近12個月)
      營運報告/法說會日期
      2021-11-15
      除權除息日
      -

    查看即時報價

  2. Moderna COVID-19 vaccine - Wikipedia

    en.wikipedia.org › wiki › Moderna_COVID-19_vaccine

    The Moderna COVID‑19 vaccine (pINN: elasomeran [24]), codenamed mRNA-1273 and sold under the brand name Spikevax, [2] is a COVID-19 vaccine developed by American company Moderna, the United States National Institute of Allergy and Infectious ...

  3. Novavax - Wikipedia

    en.wikipedia.org › wiki › Novavax
    • History
    • External Sponsorships
    • Drugs/Vaccines in Development
    • Vaccine Adjuvants
    • See Also
    • Further Reading
    • External Links

    Novavax was founded in 1987 to focus on experimental vaccine development, but as of early 2021 has not yet completed commercialization of any vaccine product. In June 2013, Novavax acquired the Matrix-M adjuvantplatform with the purchase of Swedish company Isconova AB and renamed its new subsidiary Novavax AB.

    Novavax is funded by a mix of private and public investment. In 2015, Novavax received a US$89 million research grant from the Bill and Melinda Gates Foundation to support the development of a vaccine against human respiratory syncytial virus for infants via maternal immunization. In May 2020, Novavax received US$384 million from the Coalition for Epidemic Preparedness Innovations to fund early-stage evaluation in healthy adults of the company's COVID-19 vaccine candidate NVX-CoV2373 and to develop resources in preparation for large-scale manufacturing, if the vaccine proves successful.CEPI had already invested $4 million in March.

    COVID-19 vaccine candidate

    In January 2020, Novavax announced development of a vaccine candidate, named NVX-CoV2373, to establish immunity to SARS-CoV-2. NVX-CoV2373 is a protein subunit vaccine that contains the spike protein of the SARS-CoV-2 virus.Novavax's work is in competition for vaccine development among dozens of other companies. In January 2021, the company released phase 3 trials showing that it has 89% efficacy against Covid-19, and also provides strong immunity against new variants. It has applied for emer...

    Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M,is used in one of Novavax's experimental test vaccines for COVID-19.

    "Novavax, Inc. Common Stock (NVAX) News Headlines". Market Activity. Nasdaq. Retrieved 25 January 2020.Continuously updated listing of Nasdaq publications related to Novavax, newest items first.

    • 1987; 34 years ago
    • $475.2 Million (2020)
  4. 其他人也搜尋了